Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Feverfen 100mg/5ml oral suspension
1001010J0CWABBH
|
Feverfen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Fexofenadine 125mg/5ml oral suspension
0304010E0AAAFAF
|
Fexofenadine hydrochloride | Fexofenadine hydrochloride | Respiratory System | No data available |
|
Fibrase 50mg capsules
0208020I0BBAAAB
|
Fibrase (Oral) | Pentosan polysulfate sodium | Cardiovascular System | No data available |
|
Fibro-Vein 0.2% solution for injection 5ml vials
0213000T0BDABAH
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 0.5% solution for injection 2ml ampoules
0213000T0BDAAAC
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 1% solution for injection 2ml ampoules
0213000T0BDACAD
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 3% solution for injection 2ml ampoules
0213000T0BDADAF
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibro-Vein 3% solution for injection 5ml vials
0213000T0BDAEAG
|
Fibro-Vein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrogammin 1,250unit inj vials
0211000U0BBABAB
|
Fibrogammin | Dried factor XIII fraction | Cardiovascular System | No data available |
|
Fibrogammin 250unit inj vials
0211000U0BBAAAA
|
Fibrogammin | Dried factor XIII fraction | Cardiovascular System | No data available |
|
Fibrovein 0.2% solution for injection 5ml vials
0213000T0BEABAH
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrovein 1% solution for injection 2ml ampoules
0213000T0BEADAD
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrovein 3% solution for injection 2ml ampoules
0213000T0BEAEAF
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fibrovein 3% solution for injection 5ml vials
0213000T0BEAAAG
|
Fibrovein | Sodium tetradecyl sulphate | Cardiovascular System | No data available |
|
Fiery Jack 2.466% ointment
1003020H0BCAAAH
|
Fiery Jack (Ointment) | Capsicum | Musculoskeletal and Joint Diseases | No data available |
|
Fiery Jack cream
1003020T0BJAAA0
|
Fiery Jack (Cream) | Nicotinates | Musculoskeletal and Joint Diseases | No data available |
|
Filair 100 inhaler
0302000C0BGABAB
|
Filair | Beclometasone dipropionate | Respiratory System | No data available |
|
Filair 50 inhaler
0302000C0BGAAAA
|
Filair | Beclometasone dipropionate | Respiratory System | No data available |
|
Filair Forte 250micrograms/dose inhaler
0302000C0BGACAC
|
Filair | Beclometasone dipropionate | Respiratory System | No data available |
|
Filgotinib 100mg tablets
1001030AGAAAAAA
|
Filgotinib | Filgotinib | Musculoskeletal and Joint Diseases | No data available |
|
Filgotinib 200mg tablets
1001030AGAAABAB
|
Filgotinib | Filgotinib | Musculoskeletal and Joint Diseases | No data available |
|
Filgrastim 12million units/0.2ml inj pre-filled syringes
0901060I0AAAPAP
|
Filgrastim | Filgrastim | Nutrition and Blood | No data available |
|
Filgrastim 48million units/0.8ml inj pre-filled syringes
0901060I0AAANAN
|
Filgrastim | Filgrastim | Nutrition and Blood | No data available |
|
Filgrastim 48million units/1.6ml inj vials
0901060I0AAABAB
|
Filgrastim | Filgrastim | Nutrition and Blood | No data available |
|
Filgrastim 70million units/0.73ml inj pre-filled syringes
0901060I0AAAQAQ
|
Filgrastim | Filgrastim | Nutrition and Blood | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.